Key Stability Testing Milestones Achieved for MRX1

Director Dealing

Total Voting Rights

Interims for the six months ended 31 July 2024

Ananda Developments Epilepsy Trials

Phase 1 PK Study to be conducted on MRX1

Result of General Meeting

Change of Location for General Meeting

Total Voting Rights

Notice of General Meeting

Result of WRAP Retail Offer

WRAP Retail Offer for up to £100,000

Placing and Subscription to raise c.£2.15 million

Management accounts for quarter ended 31 July 2024

Result of AGM

Graduation to Apex segment of AQSE Growth Market

Notice of AGM

Publication of Annual Report and Accounts

Promising Results from Cardiac Fibrosis Studies

Extension of Mark Ling as Senior Statutory Auditor

Quarterly Trading Statement to 30 April 2024

Response to FSA-FSS Cannabidiol Safety Assessment

Establishment of Scientific Advisory Board

Endometriosis Trial Drug Supply Agreement Signed

Quarterly Trading Statement to 31 January 2024

Appointment of Scientific Advisers

Quarterly Trading Statement to 31 October 2023

Drug Supply Agreement Signed

THC Oil Patent Application Filed

MOU signed with Nottingham Trent University

Interim Results to 31 July 2023

Issue of Convertible Loan Notes

Shareholder Update

Result of AGM

NHS SCOTLAND TO FUND MRX1 ENDOMETRIOSIS TRIAL

First Cannabinoid Medicines Launched

Unaudited Preliminary Results

Operational Update

Patent Applications Filed

Appointment of AQSE Corporate Adviser and Broker